Tower Research Capital LLC TRC Buys 15,974 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Tower Research Capital LLC TRC increased its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1,872.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 16,827 shares of the biopharmaceutical company's stock after purchasing an additional 15,974 shares during the quarter. Tower Research Capital LLC TRC's holdings in Ultragenyx Pharmaceutical were worth $708,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in RARE. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $40,463,000. Pictet Asset Management Holding SA increased its position in Ultragenyx Pharmaceutical by 125.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after buying an additional 653,088 shares during the period. First Trust Advisors LP lifted its holdings in shares of Ultragenyx Pharmaceutical by 3,097.1% during the fourth quarter. First Trust Advisors LP now owns 544,202 shares of the biopharmaceutical company's stock worth $22,894,000 after buying an additional 527,180 shares during the last quarter. Fisher Asset Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $11,156,000. Finally, Prudential Financial Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 659.5% in the fourth quarter. Prudential Financial Inc. now owns 272,940 shares of the biopharmaceutical company's stock worth $11,483,000 after acquiring an additional 237,003 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Wedbush restated a "neutral" rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Canaccord Genuity Group raised their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Piper Sandler decreased their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the sale, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 over the last 90 days. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Trading Up 1.2 %

Shares of NASDAQ RARE opened at $38.09 on Monday. The firm has a market cap of $3.58 billion, a P/E ratio of -6.01 and a beta of 0.61. The business's 50 day moving average is $37.79 and its 200-day moving average is $43.54. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The business had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.